Evidence map›Paper›PMID 36871660›Full record

ArticleThe Journal of investigative dermatology2023

Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.

Sharmeen Chagani, Mariana P De Macedo, Fernando Carapeto, Feng Wang, Diego M Marzese, Khalida Wani, Lauren E Haydu, Weiyi Peng, Giang T Ong, Sarah E Warren and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Sharmeen ChaganiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mariana P De MacedoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fernando CarapetoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Feng WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Diego M MarzeseCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands, Palma, Balearic Islands, Spain; Saint John's Cancer Institute at Saint John's Health Center, PHS, Santa Monica, California, USA.
Khalida WaniDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren E HayduDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Weiyi PengDepartment of Biology and Biochemistry, The University of Houston, Houston, Texas, USA.
Giang T OngNanoString Technologies, Inc, Seattle, Washington, USA.
Sarah E WarrenNanoString Technologies, Inc, Seattle, Washington, USA.
Joseph M BeechemNanoString Technologies, Inc, Seattle, Washington, USA.
Dave S B HoonSaint John's Cancer Institute at Saint John's Health Center, PHS, Santa Monica, California, USA.
Gordon B MillsDivision of Oncologic Sciences, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Michael T TetzlaffDepartment of Pathology, The University of California at San Francisco, San Francisco, California, USA.
Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael A DaviesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: MDavies@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USNanostring Technologies (United States) · USSaint John's Health Center · USOregon Health & Science University · USUniversity of California, San Francisco · USUniversity of Houston · US

Funding

The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
NCI NIH HHS P50 CA221703
6 · The paper itself

Abstract

Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed a unique cohort of eight melanoma samples with focal loss of PTEN protein expression to understand the features and mechanisms of PTEN loss in this disease. We compared the PTEN-negative (PTEN[-]) areas to their adjacent PTEN-positive (PTEN[+]) areas using DNA sequencing, DNA methylation, RNA expression, digital spatial profiling, and immunohistochemical platforms. Variations or homozygous deletions of PTEN were identified in PTEN(-) areas that were not detected in the adjacent PTEN(+) areas in three cases (37.5%), but no clear genomic or DNA methylation basis for loss was identified in the remaining PTEN(-) samples. RNA expression data from two independent platforms identified a consistent increase in chromosome segregation gene expression in PTEN(-) versus adjacent PTEN(+) areas. Proteomic analysis showed a relative paucity of tumor-infiltrating lymphocytes in PTEN(-) versus adjacent PTEN(+) areas. The findings add to our understanding of potential molecular intratumoral heterogeneity in melanoma and the features associated with the loss of PTEN protein in this disease.

Indexed as

MelanomaPTEN PhosphohydrolaseGenes, Tumor SuppressorHumansProteomicsRNAPTEN PhosphohydrolasePTEN protein, humanRNA

Identifiers

PMID36871660
PMCPMC10475489
OpenAlexW4323030825

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.